Thunderhouse is a communications strategy group that works exclusively to bring innovations to fruition in the shortest possible time.
Thunderhouse charts strategic pathways to success, sets forth and launches Action Plans to achieve agreed upon goals and helps overcome inevitable obstacles that crop up along the way.
ThunderHouse continues its work on high visibility innovations in the Marketing Communications industry under the NextGen MarComTM umbrella even though the industry is suffering through a malaise of business uncertainties related to the economic downturn and by advances in digital communication technologies. ThunderHouse has active projects in the areas of Targeted Digital Incentives, Marketing Communications TechnologiesTM (MCTTM) and Advanced Television Productions (ATP).
Thunderhouse is also focusing on Health Sciences, and specifically on the ElishaHeart LVAD, a major breakthrough in heart assist devices that can save the lives of thousands of late stage heart failure patients. The clinical use of LVADs has increased dramatically this past year and for the first time, LVADs are generating profits. ElishaHeart has secured U.S. and European patents for a next generation LVAD that promises to improve efficacy significantly and has a team of world class experts ready to develop a working prototype. Dr. Robert Fuisz, Lead Partner for Health Sciences, (see Team) will lead efforts to fund the development of this very promising prototype, the first in a series of innovative devices and systems invented by ElishaHeart LLC to improve the performance of the human heart.
Thunderhouse is headquartered in New York and has operating companies in Mexico and Canada.